register

Human Resources

Daiichi Sankyo Australia earns Family Inclusive Workplace Certification in record time since commencement of local operations

Health Industry Hub | October 12, 2023 |

Human Resources: In a milestone for workplace inclusivity, Daiichi Sankyo Australia announced that the company has been certified as a Family Inclusive Workplace, affirming their commitment to fostering an environment that supports employees at all stages of life.

The certification, granted in adherence to the National Work + Family Standards developed by Family Friendly Workplaces and endorsed by UNICEF Australia, signifies Daiichi Sankyo’s dedication to upholding benchmark policies and practices. These encompass a broad spectrum, including flexible work practices, parental leave, family care, and overall employee wellbeing.

Natalie Down, Head of People & Culture at Daiichi Sankyo Australia, expressed the company’s core values and aspirations, stating, “As we build our culture and our team, we have been clear from the outset that we will craft a unique employee experience with embedded flexibility to support our people to be there in the moments that matter for their families – no matter what form their families take. We celebrate our recently announced Family Inclusive Workplace Certification as a vital building block to achieving this.”

Daiichi Sankyo, having commenced operations in Australia earlier this year, is on the brink of revolutionising cancer treatment with its proprietary DXd antibody drug conjugate (ADC) technology. Presently, the company is evaluating five ADCs in its oncology portfolio for over 40 different indications, addressing cancers with unmet needs through clinical trials on a global scale.

In Australia, Daiichi Sankyo is actively cultivating a team dedicated to innovation and compassion for patients. This certification reinforces the organisation’s dedication to cultivating a workplace that encourages employees to balance their professional endeavours with family responsibilities, promoting a harmonious work-life integration.

In reimagining healthcare, Health Industry HubTM is the ONLY one-stop-hub uniting the diversity of Pharma, MedTech, Diagnostics & Biotech sectors to inspire meaningful change. The exclusive leadership and influencer podcasts and vodcasts offer unparalleled insights and add immense value to our breaking news coverage.

The Health Industry HubTM content is copyright protected. Access is available under individual user licenses. Please click here to subscribe and visit T&Cs here.


News & Trends - MedTech & Diagnostics

Government's rejection of COVID Royal Commission a stark contrast to the UK and NZ

Government’s rejection of COVID Royal Commission a stark contrast to the UK and NZ

Health Industry Hub | September 20, 2024 |

The Albanese government has dismissed the Senate legal and constitutional committee’s proposal for a COVID-19 pandemic royal commission with one […]

More


News & Trends - Biotechnology

AusBiotech and MTPConnect Unite for Landmark Summit on Australia’s Biotech and Medtech Future

AusBiotech and MTPConnect unite for landmark Summit on the nation’s biotech and medtech future

Health Industry Hub | September 20, 2024 |

AusBiotech and MTPConnect have announced an ambitious new collaboration to host Australia’s first National Biotech and Medtech Development and Commercialisation […]

More


ESG

Wear It Red Day ignites national movement for chronic pain recognition, demanding voices be heard

Wear It Red Day ignites national movement for chronic pain recognition, demanding voices be heard

Health Industry Hub | September 20, 2024 |

Today marks the first ever national Wear It Red Day. An initiative of Painaustralia, the national peak advocacy body for […]

More


News & Trends - Pharmaceuticals

Targeted therapy with Astellas’ Xtandi improves prostate cancer outcomes for Aussie patients

Targeted therapy with Astellas’ Xtandi improves prostate cancer outcomes for Aussie patients: New study

Health Industry Hub | September 20, 2024 |

Pharma News: New research from the led by the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP) […]

More


This content is copyright protected. Please subscribe to gain access.